4,884,186 Shares in Fractyl Health, Inc. $GUTS Bought by General Catalyst Group Management LLC

General Catalyst Group Management LLC purchased a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 4,884,186 shares of the company’s stock, valued at approximately $3,880,000. Fractyl Health accounts for approximately 2.1% of General Catalyst Group Management LLC’s portfolio, making the stock its 7th biggest holding. General Catalyst Group Management LLC owned approximately 3.07% of Fractyl Health as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of GUTS. Sanctuary Advisors LLC bought a new stake in Fractyl Health during the second quarter valued at $26,000. Jane Street Group LLC purchased a new stake in shares of Fractyl Health in the 2nd quarter valued at about $31,000. Accredited Investors Inc. purchased a new stake in shares of Fractyl Health in the 1st quarter valued at about $46,000. Scientech Research LLC bought a new stake in shares of Fractyl Health during the 3rd quarter valued at about $49,000. Finally, FNY Investment Advisers LLC boosted its position in shares of Fractyl Health by 84.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock valued at $51,000 after acquiring an additional 29,920 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on GUTS shares. Craig Hallum initiated coverage on shares of Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Wall Street Zen cut Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.50.

Insider Buying and Selling at Fractyl Health

In other Fractyl Health news, Director Ian Sheffield acquired 35,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the purchase, the director directly owned 35,000 shares of the company’s stock, valued at $25,550. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Bradley purchased 68,493 shares of the stock in a transaction dated Wednesday, June 10th. The stock was purchased at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the purchase, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. The trade was a 424.66% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 171,493 shares of company stock worth $127,150 over the last ninety days. Insiders own 8.52% of the company’s stock.

Fractyl Health Price Performance

NASDAQ GUTS opened at $0.74 on Friday. The company has a market capitalization of $118.08 million, a PE ratio of -0.84 and a beta of 2.32. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The business’s fifty day moving average is $0.75 and its 200 day moving average is $0.66. Fractyl Health, Inc. has a fifty-two week low of $0.38 and a fifty-two week high of $2.44.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. Sell-side analysts predict that Fractyl Health, Inc. will post -0.53 earnings per share for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.